Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/33399
Title: Phase I Safety and Immunogenicity Trial of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51
Authors: Herrera, Socrates
Lucia Fernandez, Olga
Vera, Omaira
Cardenas, William
Ramirez, Oscar
Palacios, Ricardo [UNIFESP]
Chen-Mok, Mario
Corradin, Giampietro
Arevalo-Herrera, Myriam
Malaria Vaccine & Drug Dev Ctr
Univ Valle
Ctr Med Imbanaco
Fdn Clin Valle del Lili
Universidade Federal de São Paulo (UNIFESP)
Family Hlth Int
Univ Lausanne
Issue Date: 1-Feb-2011
Publisher: Amer Soc Trop Med & Hygiene
Citation: American Journal of Tropical Medicine and Hygiene. Mclean: Amer Soc Trop Med & Hygiene, v. 84, n. 2, p. 12-20, 2011.
Abstract: We assessed the safety, tolerability, and immunogenicity of a mixture of three synthetic peptides derived from the Plasmodium vivax circumsporozoite protein formulated in Montanide ISA 720 or Montanide ISA 51. Forty healthy malaria-naive volunteers were allocated to five experimental groups (A-E): four groups (A-D) were immunized intramuscularly with 50 and 100 mu g/dose injections of a mixture of N, R, and C peptides formulated in the two different adjuvants at 0, 2, and 4 months and one group was administered placebo. Vaccines were immunogenic, safe, well tolerated, and no serious adverse events related to the vaccine occurred. Seroconversion occurred in >90% of the vaccines and antibodies recognized the sporozoite protein on immunofluorescent antibody test. Vaccines in Montanide ISA 51 showed a higher sporozoite protein recognition and interferon production. Results encourage further testing of the vaccine protective efficacy.
URI: http://repositorio.unifesp.br/handle/11600/33399
ISSN: 0002-9637
Other Identifiers: http://dx.doi.org/10.4269/ajtmh.2011.09-0516
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.